Expert Review of Neurotherapeutics最新文献

Important context missing from "contemporary perspectives in cerebral amyloid angiopathy". “脑淀粉样血管病的当代视角”中缺失的重要背景。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-06 DOI: 10.1080/14737175.2025.2571536

Polona Rus Prelog, Matija Zupan, Senta Frol

引用次数: 0

Evaluating clazosentan sodium for the treatment of aneurysmal subarachnoid hemorrhage. 克拉生坦钠治疗动脉瘤性蛛网膜下腔出血的疗效评价。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-02 DOI: 10.1080/14737175.2025.2564708

Nived Jayaraj Ranjini, Kamran A Zahoor, Pashmeen Lakhani, Jose I Suarez, Adnan I Qureshi

{"title":"Evaluating clazosentan sodium for the treatment of aneurysmal subarachnoid hemorrhage.","authors":"Nived Jayaraj Ranjini, Kamran A Zahoor, Pashmeen Lakhani, Jose I Suarez, Adnan I Qureshi","doi":"10.1080/14737175.2025.2564708","DOIUrl":"10.1080/14737175.2025.2564708","url":null,"abstract":"Introduction: Delayed cerebral ischemia (DCI), often linked to cerebral vasospasm, is a major cause of death and disability after aneurysmal subarachnoid hemorrhage (aSAH). Nimodipine remains the only Food and Drug Administration (FDA)-approved drug for DCI prevention.Areas covered: The authors review clazosentan, a selective endothelin-A receptor antagonist approved in Japan and South Korea. This drug profile is based on searches utilizing PubMed/MEDLINE, Embase, Cochrane Library, Web of Science, and Google Scholar from database inception through to March 2025 using terms including 'clazosentan,' 'aneurysmal subarachnoid hemorrhage,' 'cerebral vasospasm,' 'delayed cerebral ischemia,' and trial identifiers (CONSCIOUS, REACT, REVERSE). The authors included Phase I-IV clinical studies, PK/PD studies, and meta-analyses; preclinical reports and non-peer-reviewed abstracts were excluded, prioritizing randomized controlled trials and large syntheses.Expert opinion: Clazosentan consistently reduces angiographic vasospasm and vasospasm-related complications, yet durable improvements in functional outcomes have been inconsistent across international trials. Safety concerns like pulmonary complications, anemia, and fluid retention require vigilant monitoring, particularly in elderly or hepatically impaired patients. Recent Japanese Phase III trials and real-world cohorts suggest benefit in selected populations and practice settings, supporting clazosentan as an adjunct to standard care rather than a replacement. Further work should refine dosing, patient selection, and combination strategies that target microvascular dysfunction and neuroinflammation beyond large-vessel spasm.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of sleep apnea on epilepsy treatment outcomes. 睡眠呼吸暂停对癫痫治疗结果的影响。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-25 DOI: 10.1080/14737175.2025.2546866

Milena Pavlova, Reza Radmand, Jeff Lee, Jennifer Grom, Sogol Javaheri, Sanaya Daruvala

引用次数: 0

Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder. 视神经脊髓炎谱系障碍的治疗进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-09-17 DOI: 10.1080/14737175.2025.2548947

Jayne Chamberlain, Pakeeran Siriratnam, Saif Huda

{"title":"Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder.","authors":"Jayne Chamberlain, Pakeeran Siriratnam, Saif Huda","doi":"10.1080/14737175.2025.2548947","DOIUrl":"10.1080/14737175.2025.2548947","url":null,"abstract":"Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune disorder of the central nervous system, characterized by inflammatory attacks affecting the optic nerves, spinal cord and brain. In most cases, pathogenic antibodies against aquaporin-4 (AQP4-IgG) are detectable. These antibodies target astrocytes, triggering complement activation and the release of proinflammatory cytokines such as interleukin-6 (IL-6), culminating in an astrocytopathy and neurological disability.Areas covered: In this review, Medical Subject Heading (MeSH) and related entry terms were used to search English literature in PubMed and ClinicalTrial.gov databases, respectively. MeSH included but were not limited to Neuromyelitis optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD), pathogenesis, complement, immune cells, B-cell, T-cell, cytokines, and therapy.Expert opinion: Over the past decade, significant strides in our understanding of NMOSD immunopathogenesis have led to the development of targeted therapies that have revolutionized patient outcomes and survival. This review outlines the clinical features of NMOSD and examines current and emerging therapeutic strategies in the context of disease biology. It also addresses ongoing challenges, including optimization of acute attack management, strategies for treatment de-escalation, and prospects for achieving immune tolerance.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1235-1256"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of transcranial direct current stimulation for tic symptoms in Tourette's syndrome. 经颅直流电刺激治疗抽动症的综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-30 DOI: 10.1080/14737175.2025.2548330

Jessica Frey, Irene Malaty

{"title":"An overview of transcranial direct current stimulation for tic symptoms in Tourette's syndrome.","authors":"Jessica Frey, Irene Malaty","doi":"10.1080/14737175.2025.2548330","DOIUrl":"10.1080/14737175.2025.2548330","url":null,"abstract":"Introduction: While there are many treatment options available for Tourette Syndrome, including pharmacotherapy and behavioral therapy, these treatments may lead to incomplete symptom relief or side effects. Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation technique that uses constant, low current delivered via electrodes attached to the scalp in order to modulate brain signals. tDCS has been explored as an alternative treatment option for tics in both pediatric and adult populations. While some studies have demonstrated that cathodal tDCS over the Supplementary Motor Area leads to improvement in tics compared to baseline as well as trends toward improvement in tics compared to sham stimulation, other studies have had mixed results or worsening of symptoms.Areas covered: Herein, the authors discuss the recent studies on tDCS for Tourette syndrome and highlight the most common side effects found. The authors also comment on the limitations these studies have and provide their expert perspectives on its prospects as a treatment option. This article is based on a PubMed literature focusing on the terms 'transcranial direct current stimulation OR tDCS' AND 'tic OR Tourette.'Expert opinion: While tDCS is a promising treatment to explore, it is premature to recommend it as a primary or adjunctive therapy outside the experimental setting. The optimal stimulation protocol, brain target, and treatment duration have yet to be elucidated; therefore, additional larger, sham-controlled, randomized studies are needed to determine the best way to incorporate tDCS into clinical practice.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1165-1173"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing personalized treatment strategies for Parkinson's disease based on disease subtypes. 基于疾病亚型开发帕金森病的个性化治疗策略。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI: 10.1080/14737175.2025.2552784

Grace E Hey, Robert Eisinger, Diego Guarin, Delaram Safarpour, Mayela Rodríguez-Violante, Adolfo Ramirez-Zamora

{"title":"Developing personalized treatment strategies for Parkinson's disease based on disease subtypes.","authors":"Grace E Hey, Robert Eisinger, Diego Guarin, Delaram Safarpour, Mayela Rodríguez-Violante, Adolfo Ramirez-Zamora","doi":"10.1080/14737175.2025.2552784","DOIUrl":"10.1080/14737175.2025.2552784","url":null,"abstract":"Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by classic motor symptoms such as tremor, bradykinesia, rigidity, and postural instability as well as several non-motor symptoms. The heterogenous nature of PD has increased interest in classifying patients into subtypes based on clinical and/or pathologic features. This approach might allow for personalized therapies ranging from non-medical interventions to disease modifying therapies.Areas covered: As the field continues to advance, PD can be classified into simple motor, non-motor, or genetic subtypes among many others, though more complex subtypes have emerged because of artificial intelligence (AI) and machine learning (ML) systems. Herein, the authors describe the current state of subtyping in PD and the effects of subtyping on the development of personalized PD treatment strategies. The article was based on a literature search using PubMed to identify relevant peer-reviewed articles on PD subtypes and treatment strategies.Expert opinion: Subtyping PD effectively may allow for the development of patient-specific treatment regimens, disease prediction strategies, and improved clinical trial designs, though limitations exist. Future investigations should aim to provide more robust subtyping criteria that allows for disease fluidity.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1175-1194"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging role for radiomics in the management of intracranial arteriovenous and cavernous malformations. 放射组学在颅内动静脉和海绵体畸形治疗中的新作用。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-15 DOI: 10.1080/14737175.2025.2548328

Samuel A Tenhoeve, Timothy Wardrop, Alec Smith, William T Couldwell, Robert C Rennert

{"title":"Emerging role for radiomics in the management of intracranial arteriovenous and cavernous malformations.","authors":"Samuel A Tenhoeve, Timothy Wardrop, Alec Smith, William T Couldwell, Robert C Rennert","doi":"10.1080/14737175.2025.2548328","DOIUrl":"10.1080/14737175.2025.2548328","url":null,"abstract":"Introduction: Intracranial arteriovenous malformations (AVMs) and cavernous malformations (CMs) pose substantial diagnostic, prognostic, and therapeutic challenges. Traditional imaging techniques used for AVM/CM diagnostic and treatment decision-making are limited by subjectivity and reliance on human interpretation. Radiomics, an artificial intelligence-driven technique that extracts quantitative imaging biomarkers, is a promising tool for improving detection, risk assessment, and treatment planning.Areas covered: The use of radiomic data for diagnosis, clinical course prediction, and outcome forecasting in patients with AVMs/CMs is reviewed, following a comprehensive search of the PubMed database for iterative terms of 'radiomics,' 'arteriovenous malformations,' and 'cavernous malformations.' Radiomic techniques demonstrate high diagnostic accuracy for differentiating AVM-related hemorrhages from other causes. Additionally, radiomic models have shown promise in predicting AVM rupture risk, epilepsy occurrence, and response to radiosurgery. In limited studies, radiomics have also shown utility in distinguishing CMs from other intracranial lesions and predicting CM hemorrhage risk.Expert opinion: Radiomics may enhance personalized neurosurgical decision-making and patient outcomes for AVMs and CMs. Ongoing technological refinements, iterative testing, and addressing barriers to equitable access to this technology will be critical for widespread application.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1223-1233"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging pharmacotherapeutic options for the treatment of lennox-gastaut syndrome: moving forward in 2025. 治疗lenox -胃综合征的新药物治疗方案：2025年的进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-22 DOI: 10.1080/14737175.2025.2549500

Giovanni Battista Dell'Isola, Pasquale Striano, Alberto Verrotti

引用次数: 0

Novel approaches for the treatment of frontotemporal dementia: is there hope for the future? 治疗额颞叶痴呆的新方法：未来有希望吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-13 DOI: 10.1080/14737175.2025.2546867

Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Giancarlo Sborgia, Antonio Daniele, Vincenzo Solfrizzi, Emanuela Resta, Francesco Panza

{"title":"Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?","authors":"Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Giancarlo Sborgia, Antonio Daniele, Vincenzo Solfrizzi, Emanuela Resta, Francesco Panza","doi":"10.1080/14737175.2025.2546867","DOIUrl":"10.1080/14737175.2025.2546867","url":null,"abstract":"Introduction: Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized clinically by behavioral disturbances and pathologically by frontal and anterior temporal lobe neurodegeneration, resulting in brain atrophy. No disease-modifying therapy currently exists for FTD. Familial FTD is primarily caused by three major genetic mutations, extensively investigated during the preclinical phases. Compounds developed to date have been designed to target specific mutations. A shift to broader approaches targeting abnormal protein deposition must employ endpoints that are meaningful to genetic and sporadic FTD, despite the diversity of their symptoms.Areas covered: The authors review the most recent pharmacological and non-pharmacological randomized clinical trials (RCTs), focusing on the molecules involved, mechanisms of action, and pharmacological testing. The present review article is based on multiple database searches (MEDLINE, EMBASE, Scopus, Ovid, and Google Scholar) on all the available literature up to the 1 May 2025.Expert opinion: Ongoing RCTs aimed to evaluate new disease-modifying or symptomatic treatment for FTD and to determine whether therapeutic strategies should target specific genetic mutations or focus on common protein deposits in the brain. These studies are laying the groundwork for future innovations. This shift could enable the transition from treating genetic FTD to tackling sporadic cases as well.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1195-1208"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144845063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donanemab for Alzheimer's disease: from preclinical research to the clinical application. Donanemab治疗阿尔茨海默病：从临床前研究到临床应用。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-10-01 Epub Date: 2025-08-25 DOI: 10.1080/14737175.2025.2546868

Richard Dodel, Lutz Frölich

{"title":"Donanemab for Alzheimer's disease: from preclinical research to the clinical application.","authors":"Richard Dodel, Lutz Frölich","doi":"10.1080/14737175.2025.2546868","DOIUrl":"10.1080/14737175.2025.2546868","url":null,"abstract":"Introduction: Donanemab (Kisunla) is a humanized IgG1 monoclonal antibody specifically targeting a modified form of β-amyloid found predominantly within plaques (characterized as N-terminal pyroglutamate Aβ). Recently, it has gained approval for the use in early-stage Alzheimer's disease (AD) encompassing mild cognitive impairment due to AD or mild AD with confirmed brain amyloid pathology.Areas covered: This drug profile discusses donanemab's function, clinical effectiveness, safety, tolerability, health economics, access challenges, and future prospects. This article is based on systematic review that was derived from PubMed.Expert opinion: Donanemab is the third monoclonal antibody introduced for the treatment of individuals in the early stage of AD. While critical dialog continues regarding the potential impacts and role of antibody therapies, its approval signifies considerable progress in addressing the underlying pathology of AD. The authors are confident in the potential of antibodies against Aβ as a promising treatment option and foresee exciting advancements. However, further research is needed on trials extending beyond 18 months of follow-up, postmarketing surveillance, and the application of donanemab in combination with existing treatments and lifestyle interventions. Additionally, significant knowledge gaps and implementation limitations persist and must be addressed.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1151-1163"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0